Nanobodies News and Research

RSS

Promising nanobodies against COVID-19 produced by llamas

News-Medical speaks to Dr. David Brody about his latest research that involved discovering nanobodies produced by llamas that could help combat coronavirus.

25 Jan 2021

South African SARS-CoV-2 variant escapes antibody neutralization

Researchers in South Africa have conducted a study showing that the novel 501Y.V2 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has emerged in the country is able to escape the neutralizing antibodies that are elicited by previously circulating strains of the virus.

20 Jan 2021

Researchers develop novel antibody fragments against SARS coronavirus-2

An international research team led by the University of Bonn (Germany) has identified and further developed novel antibody fragments against the SARS coronavirus-2. These "nanobodies" are much smaller than the classic antibodies used to treat US President Donald Trump, for example.

13 Jan 2021

New publication describes DiosCURE’s multivalent single-chain antibodies to inactivate SARS-CoV-2

DiosCURE SE announced a publication in Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE.

13 Jan 2021

Nanobodies have potential to be developed into a treatment for COVID-19

Researchers at Karolinska Institutet in Sweden have developed, in collaboration with researchers in Germany and the U.S., new small antibodies, also known as nanobodies, which prevent the SARS-CoV-2 coronavirus from entering human cells.

12 Jan 2021

New approach to tame botulinum toxin for drug delivery

While rare, botulism can cause paralysis and is potentially fatal. It is caused by nerve-damaging toxins produced by Clostridium botulinum -- the most potent toxins known.

8 Jan 2021

Non-toxic versions of botulism toxins can deliver therapeutic antibodies to treat botulism

Taking advantage of the chemical properties of botulism toxins, two teams of researchers have fashioned non-toxic versions of these compounds that can deliver therapeutic antibodies to treat botulism, a potentially fatal disease with few approved treatments.

6 Jan 2021

Scientists isolate anti-COVID-19 nanobodies produced by a llama

National Institutes of Health researchers have isolated a set of promising, tiny antibodies, or "nanobodies," against SARS-CoV-2 that were produced by a llama named Cormac.

22 Dec 2020

SARS-CoV-2 Nsp3 protease activity and nanobody inhibitor development

A new study published in the pre-print server bioRxiv* explores the viral enzyme PLpro, encoded in the nonstructural protein nsp3, and its inhibitors. T

14 Dec 2020

UCI researchers develop new technology to rapidly hypermutate antibodies

Using the same strain of yeast that ferments wine and makes dough rise, a team led by University of California, Irvine and Harvard Medical School researchers has developed an in vitro technology that can rapidly hypermutate antibodies.

8 Dec 2020

Researchers use novel technology to prevent destruction of specific proteins inside cells

Columbia researchers have created a new technology using synthetic llama antibodies to prevent specific proteins from being destroyed inside cells.

8 Dec 2020

Novel modular design approach to antibody nanocage generation

A new study shows the benefits of using computational design to create antibody nanocages that have the required orientation.

7 Dec 2020

Bioelectronic rapid test for COVID-19

A recent study presents a bioelectronic sensor platform to detect protein at the single-molecule level that is simple, rapid, and robust enough for widespread POC (point-of-care) or bedside application.

18 Nov 2020

Nanobodies: unharnessed potential in COVID-19 treatment

A new study published in the Journal of Biomolecular Structure and Dynamics in October 2020 discusses the use of nanobodies in diagnosing and treating this deadly disease.

16 Nov 2020

Bispecific sybodies show potential against SARS-CoV-2

As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November 2020 discusses the role of synthetic nanobodies or sybodies in neutralizing the virus by binding to its receptor-binding domain (RBD) on the spike protein.

12 Nov 2020

Llama antibodies could be a potent nanoweapon against COVID-19

Today in Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19.

5 Nov 2020

Nanobodies efficiently neutralize SARS-CoV-2 in cells

Two separate studies have identified nanobodies - which could be produced less expensively than monoclonal antibodies - that bind tightly to the SARS-CoV-2 spike protein and efficiently neutralize SARS-CoV-2 in cells.

5 Nov 2020

Researchers identify antibodies that prevent SARS-CoV-2 from infecting human cells

The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2.

5 Nov 2020

Synthetic antibody may prevent coronavirus from infecting human cells

By screening hundreds of synthetic antibodies, researchers at Karolinska Institutet in Sweden and EMBL Hamburg in Germany have identified an antibody that may prevent the new coronavirus from infecting human cells.

4 Nov 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020